Search the Site
Follow TheCancerLetter on Twitter
join our mailing list

Enter your name and email address to receive an update when we post new content.

IP Login

 

The Cancer Letter Inc.
PO Box 9905
Washington
DC 20016
Tel: 202-362-1809
Fax: 202-379-1787
publication date: May 13, 2016
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.

Drugs and Targets

FDA Expands Imbruvica Label To Include CLL and SLL Patients 

 

FDA approved an expansion to the Imbruvica (ibrutinib) prescribing information based on data supporting its use in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma.

The approved label now includes overall survival data from the Phase III RESONATE-2 (PCYC-1115) trial in treatment-naïve CLL/SLL patients 65 years or older. The updated label also contains clinical data from the phase III HELIOS (CLL3001) trial investigating the use of Imbruvica in combination with bendamustine and rituximab versus placebo plus BR in patients with relapsed or refractory CLL/SLL.



To access this members-only content, please log in.

If you're not a subscriber why not join today?

If you believe you should be able to view this area but cannot log in, then please contact us and we will try to rectify this issue as soon as possible.


To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Letter